The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025.<\/p>\n
Tom Little | Reuters<\/p>\n
Novo Nordisk<\/a> will start rolling out the first-ever GLP-1 pill for weight loss<\/a> in the U.S. on Monday, the company announced, marking a new chapter of obesity treatment<\/a> in the U.S.\u00a0<\/p>\n The drug’s cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose. That fuels hopes that pills could help address the long-standing affordability hurdles<\/a> tied to the weekly injections dominating the weight loss drug market. <\/p>\n The official launch of the oral drug, called the Wegovy pill<\/a>, comes just two weeks after U.S. regulators cleared the treatment<\/a>.\u00a0<\/p>\n The starting dose of 1.5 milligrams is available at more than 70,000 U.S. pharmacies such as CVS<\/a> and Costco<\/a>, as well as select telehealth providers, including Ro, LifeMD, Weight Watchers<\/a>, GoodRx and Novo Nordisk’s NovoCare Pharmacy. The higher, remaining doses of the pill will be available to patients by the end of the week, Novo Nordisk said.\u00a0<\/p>\n Cash-paying patients can pay $149 per month for the starting dose. The 4-milligram dose of the pill will also be available for $149 per month through April 15, then $199 per month after that.\u00a0<\/p>\n The highest doses of the Wegovy pill \u2013 9 milligrams and 25 milligrams \u2013 will be available for $299 per month. Patients with insurance coverage for the drug can pay as little as $25 per month for the treatment.\u00a0<\/p>\n Cash-paying patients will also be able to access the starting dose of the pill for $149 per month on President Donald Trump<\/a>‘s direct-to-consumer website, TrumpRx, under a deal Novo Nordisk struck<\/a> with his administration in November. The site also launches in January, though it’s unclear when.\u00a0<\/p>\n Novo Nordisk on Monday said the pill’s availability “opens new possibilities” for the more than 100 million Americans living with obesity.\u00a0<\/p>\n Injections from Novo Nordisk and its chief rival, Eli Lilly<\/a>, carry a list price of roughly $1,000 per month. But both companies offer lower cash-pay prices<\/a> for their shots that range from $299 to $499 monthly, depending on the dose.\u00a0<\/p>\n